Conexeu Sciences (NASDAQ:CNXU) & Nanovibronix (NASDAQ:FEED) Critical Contrast

Conexeu Sciences (NASDAQ:CNXU) and Nanovibronix (NASDAQ:FEED) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

16.4% of Nanovibronix shares are held by institutional investors. 5.2% of Nanovibronix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Conexeu Sciences and Nanovibronix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
Nanovibronix	-923.20%	-54.25%	-43.10%

Earnings & Valuation

This table compares Conexeu Sciences and Nanovibronix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
Nanovibronix	$2.55 million	1.23	-$18.18 million	($8.82)	-0.06

Conexeu Sciences has higher earnings, but lower revenue than Nanovibronix.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Conexeu Sciences and Nanovibronix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	0	0	1	0	3.00
Nanovibronix	1	0	0	0	1.00

Conexeu Sciences presently has a consensus target price of $20.00, indicating a potential upside of 83.15%. Given Conexeu Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Conexeu Sciences is more favorable than Nanovibronix.

Summary

Conexeu Sciences beats Nanovibronix on 6 of the 9 factors compared between the two stocks.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University’s right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company’s only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix (“ECM”) formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the “10 Minute Tissue™” concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration (“FDA”) clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.